Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Coley Pharmaceutical
This week's roundup includes executive appointments by Gilead Sciences, Nordic Nanovector, Mereo BioPharma, vasopharm and Rigontec. Biogen has also appointed two executives to its planned spin-off company, Bioverativ.
Pfizer’s emphasis on oncology has yielded three new drug approvals in the last 20 months and another two promising drugs on the horizon. It is a notable achievement, but investors may be wondering when the results are going to be felt on the top line.
Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.
Plus news on recent financings by Neurocrine Biosciences, Prosensa, RaNA Therapeutics and Trius Therapeutics.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.